Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV). It is still a major public health problem with 250 million chronically HBV-infected patients worldwide with none of the current treatments leading to a cure.
More effective treatments are needed to achieve HBV cure in a large proportion of patients.
We aim to develop a treatment, combining simultaneous stimulation of CD40 and IFN-I pathway, which leads to a strong anti-HBV effect with minimal inflammation.
In this poster we:
- Present the key results that demonstrated the potential of such combination to induce anti-HBV effects in vitro and in vivo
- Introduce the design of our new antibody-based therapeutic that combine the two modalities in one single molecule
- Demonstrate the efficacy of the molecule in HBV infection system in Primary Human Hepatocytes
- Show key results from our preclinical safety assessment in vitro and in vivo in Non-Human Primate